from PR Newswire
from PR Newswire
from PR Newswire
(NASDAQ: KERX) Rated a "BUY" by 5 Wall Street Firms
January 27, 2011
(NASDAQ: KERX) Under The Radar
January 24, 2011
(OTC: SPPH) Ready to Take a Piece of $18 Billion Market
October 29, 2010
Novartis Drug SOM230 is First Medical Therapy to Show Efficacy in a Phase III Trial in Cushing's Disease, a Debilitating Hormonal Disorder
September 22, 2010
SOM230 reduced urinary free cortisol (UFC) levels in majority of patients; 26% of patients randomized to SOM230 900ug achieved normal UFC levels Read More
from PR Newswire
Critical Alerts for Wal-Mart, Comcast, Gap, Novartis, and Crocs Released by Seven Summits Research
September 15, 2010
from PR Newswire
GenVec Achieves First Milestone in Collaboration
September 14, 2010
from PR Newswire
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here







